Author

Christian Werno

Fraunhofer Institute for Toxicology and Experimental MedicineORCID 0009-0001-1647-4804Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Christoph A. KleiniD· 2 shared Kathrin WeideleiD· 2 shared Melanie Werner‐KleiniD· 2 shared Steffi TreitschkeiD· 2 shared Aleksandra MarkiewicziD· 1 shared Alexander RochwargeriD· 1 shared Andrea StutziD· 1 shared Anja UlmeriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Christoph A. KleinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintFeb 9, 2026

Ex vivo drug testing in metastatic biopsies reveals patient-specific vulnerabilities to cancer targeting and immune activating drugs

Lukas Wöhrl, Durdam Das, Kathrin Weidele…·Christian Werno

This study introduces PEDRA, an ex vivo drug response assay that identifies patient-specific treatment options in metastatic biopsies, outperforming prior therapies and informing immune responses.

DOI 10.64898/2026.02.06.704037

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyNature CancerPeer-reviewedMay 16, 2025

Metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization

Severin Guetter, Courtney König, Huiqin Koerkel-Qu…·Melanie Werner‐Klein

This study identifies MCSP+ melanoma cells as early metastasis founder cells in lymph nodes and shows they activate immunosuppression to evade CD8 T cell attack.

18 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky